NCT06562621View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 1, 2022

Study Completion Date

March 1, 2024

Conditions
Glioblastoma MultiformeGliomas, Malignant
Interventions
BIOLOGICAL

ON-01

ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.

DRUG

ONF

ONF is an extended-release formulation of flucytosine.

Trial Locations (1)

100050

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Neurosurgical Institute

OTHER

NCT06562621 - Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter